EMA publishes revised reflection paper on heat treatment against endogenous retroviruses in live veterinary vaccines
Revision 1 of the EMA reflection paper covers heat inactivation of endogenous retroviruses in live immunological veterinary medicines, though the available material does not say what has changed.
The European Medicines Agency (EMA) has published Revision 1 of its reflection paper on using heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products. The document is dated 13 November 2026.
The material available to VigiEye does not include the text of the paper or a list of changes from the earlier version. It is therefore not possible to say which sections were revised, whether the scientific position has shifted, or what the agency now expects of manufacturers.
The publication does indicate that EMA has updated its thinking on viral safety and manufacturing controls for this product category. Live immunological veterinary medicines, which include live vaccines, are often produced in cell-based systems, where the presence of endogenous retroviruses is a recognised concern.
As context, EMA reflection papers set out the agency's current scientific thinking on a topic. They are not legally binding, but sponsors and manufacturers commonly use them to inform development plans and regulatory submissions.
What it means for your team
- Obtain the full Revision 1 text from EMA and compare it with the previous version to identify any changes.
- Manufacturers of live immunological veterinary products should check whether current viral safety strategies and manufacturing controls remain consistent with the revised paper.
- Quality assurance and regulatory teams should consider whether any dossier content or planned variations relating to heat treatment need review once the details are confirmed.
Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
RegulatoryCompany releaseImricor starts US launch of NorthStar iMR system after paediatric FDA clearances
RegulatoryCompany releaseBeyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
RegulatoryCompany releaseFDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
RegulatoryCompany release